Tenofovir Disoproxil Fumarate / Emtricitabine 300mg/200mg Tablet

Recovir-EM 300mg/200mg film-coated Tablets, 30s HDPE bottle. Treatment of HIV-1 infection in combination with other antiretroviral agents

Share Now

Name Tenofovir Disoproxil Fumarate / Emtricitabine
Description Emtricitabine is a nucleoside analogue of cytidine. Tenofovir disoproxil is converted in vivo to tenofovir, a nucleoside monophosphate (nucleotide) analogue of adenosine monophosphate. Both emtricitabine and tenofovir have activity that is specific to human immunodeficiency virus (HIV-1 and HIV-2) and hepatitis B virus. Emtricitabine and tenofovir are phosphorylated by cellular enzymes to form emtricitabine triphosphate and tenofovir diphosphate, respectively. In vitro studies have shown that both emtricitabine and tenofovir can be fully phosphorylated when combined together in cells. Emtricitabine triphosphate and tenofovir diphosphate competitively inhibit HIV-1 reverse transcriptase, resulting in DNA chain termination. Both emtricitabine triphosphate and tenofovir diphosphate are weak inhibitors of mammalian DNA Polymerases
Active Ingredient Tenofovir Disoproxil Fumarate / Emtricitabine
Indication Tenofovir disoproxil fumarate / Emtricitabine tablets is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults and treatment of HIV-1 infected adolescents. Additionally, it is also indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk.
Strengths 300mg/200mg Tablet
Business Partner Mylan
Origin India